News
BIAF
2.910
+2.83%
0.080
Weekly Report: what happened at BIAF last week (0408-0412)?
Weekly Report · 3d ago
Weekly Report: what happened at BIAF last week (0401-0405)?
Weekly Report · 04/08 11:03
bioAffinity Tech: Notice of Effectiveness
Press release · 04/08 10:24
12 Health Care Stocks Moving In Friday's Intraday Session
Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutic shares increased by 20.66% and Ocugen stock moved upwards by 17.88%. Candel Therapeutical is one of the top gainers in the sector.
Benzinga · 04/05 16:31
bioAffinity Technologies files to sell 1.63M shares for holders
BioAffinity Technologies files to sell 1.63M shares for holders. The company filed a prospectus related to the proposed resale of about 1.62M shares of common stock. The stock is listed on the Nasdaq under the name bioAffinity.
Seeking Alpha · 04/04 21:14
BIOAFFINITY TECHNOLOGIES INC - FILED PROSPECTUS RELATES TO RESALE FROM TIME TO TIME OF UP TO 1.6 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS
Reuters · 04/04 21:08
bioAffinity Technologies Q4 EPS $(0.26) Up From $(0.44) YoY, Sales $2.21M Down From $2.35M YoY
BioAffinity Technologies reported quarterly losses of $0.26 per share. The company reported $2.21 million in sales this quarter. This is a 5.67 percent decrease over sales of the same period last year. The company also reported a 40.91 percent increase in sales for the quarter.
Benzinga · 04/02 11:59
BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023
BioAffinity Technologies reported results for the fourth quarter of 2023. The company reported earnings per share of -26 cents and revenue of $2.21 million. The company is a supplier of medical equipment to the military and other industries. BioAffinity reported quarterly earnings of $0.01 per share.
Investorplace · 04/02 02:53
Press Release: bioAffinity Technologies Reports -2-
Forward-looking statements are based on the Company's current expectations and assumptions. The Company's actual results could differ materially from current expectations. The Company does not undertake to update any forward-looking statement. The company has no obligation to do so. The company's assets include cash and cash equivalents and investments.
Dow Jones · 04/01 13:49
*BioAffinity Technologies 4Q Rev $2.2M >BIAF
Dow Jones · 04/01 13:49
Press Release: bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
BioAffinity Technologies reports fourth quarter and full year 2023 revenue of $2.5 million. The company is focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. CyPath(R) Lung tests reported accelerating growth of 350% in the first quarter of 2024.
Dow Jones · 04/01 13:49
Weekly Report: what happened at BIAF last week (0325-0329)?
Weekly Report · 04/01 11:01
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
BioAffinity Technologies, Inc. Reports financial results for the three and 12 months ended December 31, 2023. The company is focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company reported fiscal year 2023 revenue of $2.5 million and increasing sales of CyPath® Lung, the Company's test to detect lung cancer. The Centers for Medicare and Medicaid Services final determination for payment for CyPath  for the 2024 calendar year.
Barchart · 04/01 08:49
Weekly Report: what happened at BIAF last week (0318-0322)?
Weekly Report · 03/25 11:04
Weekly Report: what happened at BIAF last week (0311-0315)?
Weekly Report · 03/18 11:02
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Mesoblast shares jumped 13.4% to $2.4399 on Monday. The company announced FDA support of an accelerated approval pathway for end-stage heart failure patients. Kidpik Corp. Shares gained 238% in today's mid-day session.
Benzinga · 03/11 17:41
12 Health Care Stocks Moving In Monday's Intraday Session
Regencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) shares increased by 76.41% during the session. Mesoblast stock rose 22.79% and Graphite Bio stock moved upwards.
Benzinga · 03/11 17:31
Weekly Report: what happened at BIAF last week (0304-0308)?
Weekly Report · 03/11 10:59
Press Release: Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 million Registered Direct Offering and Concurrent Private Placement. WallachBeth Capital is a leading provider of capital markets and institutional execution services. The company has closed a securities purchase agreement with institutional investors for the purchase and sale of shares of common stock.
Dow Jones · 03/08 18:15
Nasdaq Gains 100 Points; Campbell Soup Earnings Top Views
U.S. Stocks traded higher toward the end of trading on Wednesday. The Dow traded up 0.20% to 38,662.69 while the Nasdaq Composite gained around 100 points. Campbell Soup Company reported better-than-expected earnings for its second quarter. Information technology shares jumped by 1.1% on Wednesday; consumer discretionary shares fell 0.3%. Euro zone European shares closed higher while Asian markets closed mixed.
Benzinga · 03/06 19:35
More
Webull provides a variety of real-time BIAF stock news. You can receive the latest news about bioAffinity Tech through multiple platforms. This information may help you make smarter investment decisions.
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.